Media Newsroom of

Morphogen-ix Ltd

Babraham Research Campus (Building B280)
Cambridge CB22 3AT

Morphogen-ix is developing recombinant bone morphogenic proteins (BMPs) as disease-modifying therapeutics in pulmonary arterial hypertension (PAH) and other diseases characterised by endothelial cell dysfunction.

Morphogen-IX Raises £18.4M ($23.2M) in a Series B Financing

Morphogen-IX Ltd, a biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), today announced completion of a £18.4 million round of financing. The Series B was led by Medicxi, alongside investments from Cambridge…

Morphogen-IX Announces MGX292 as Clinical Development Candidate

​Morphogen-IX Ltd, a biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), today announced the nomination of its clinical development candidate and initiation of formal preclinical development. The agent, MGX292,…

Morphogen-Ix Appoints CEO and Forms Global Scientific Advisory Board

​Morphogen-IX, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Professor Nick Morrell as CEO.  Morrell co-founded the company in 2015 based on research…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login